Pharmaceutical

AbbVie gains FDA approval for EPKINLY in follicular lymphoma

AbbVie has announced the receipt of accelerated approval from the US FDA for EPKINLY to treat adults with follicular lymphoma.

Jun 28, 2024 - 04:00
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
AbbVie has announced the receipt of accelerated approval from the US FDA for EPKINLY to treat adults with follicular lymphoma.
Read the original article

Tags:

Previous Article

FDA issues complete response to Daiichi Sankyo-MSD’s BLA for NSCLC

Next Article

Unlocking brain health: The power of Cognizin® Citicoline revealed

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Contact sports cause CTE. So why are Americans watching more football than ever?

Opinion: Contact sports cause CTE. So why are Americans...

Feb 9, 2024

FDA shares new draft guidance for accelerated approval

FDA shares new draft guidance for accelerated approval

Dec 7, 2024

AbbVie’s RINVOQ now indicated for paediatric arthritis in US

AbbVie’s RINVOQ now indicated for paediatric arthritis ...

Jun 6, 2024